Related Experiment Videos
Diagnosis of coronary artery disease using dipyridamole thallium-201 imaging
C L Chao1, Y T Lee, P U Chieng
1Department of Internal Medicine, National Taiwan University Hospital, Taipei, R.O.C.
Insights
Dipyridamole thallium-201 imaging is a safe and effective noninvasive diagnostic tool for coronary artery disease. This method shows high sensitivity and specificity, offering an alternative to exercise thallium-201 scintigraphy.
Area of Science:
- Cardiology
- Nuclear Medicine
- Diagnostic Imaging
Background:
- Coronary artery disease (CAD) diagnosis often relies on invasive or stress-based imaging.
- Noninvasive alternatives are crucial for patient safety and accessibility.
Purpose of the Study:
- To evaluate the safety and diagnostic efficacy of dipyridamole thallium-201 imaging.
- To compare its performance against exercise thallium-201 scintigraphy for CAD diagnosis.
Main Methods:
- Single-photon emission computed tomography (SPECT) with dipyridamole thallium-201 was performed in 109 CAD patients and 35 normal subjects.
- Intravenous dipyridamole (0.56 mg/kg) was administered, with aminophylline used to reverse side effects.
- Coronary angiography served as the gold standard for CAD documentation.
Main Results:
- The procedure was generally safe, with common side effects including chest pain (41%), dizziness (20%), and headache (16%).
- Aminophylline effectively reversed side effects in 98% of affected patients.
- Per-patient sensitivity was 95% and specificity was 77% for CAD detection.
- Vessel-specific sensitivities ranged from 67% to 89%, and specificities from 85% to 97%.
Conclusions:
- Dipyridamole thallium-201 imaging is a safe and effective noninvasive method for diagnosing coronary artery disease.
- It serves as a viable alternative to exercise thallium-201 scintigraphy.
- The imaging technique demonstrates good diagnostic accuracy for both overall CAD and individual coronary arteries.
Abstract:
Dipyridamole thallium-201 imaging, using single-photon emission computed tomography, was evaluated for its safety and diagnostic efficacy in 109 patients with angiographically documented coronary artery disease and 35 normal subjects. The most common side effects after the intravenous administration of dipyridamole thallium-201 (0.56 mg/kg) included chest pain in 41 patients, dizziness in 20 patients, headache in 16 patients, and ST segment depression > or = 1 mm in 15 patients. Aminophylline was required to reverse the side-effects in 46 patients, and 45 of the 46 patients experienced complete relief of symptoms. Of the 109 patients with coronary artery disease, 104 had abnormal dipyridamole thallium images. The per patient sensitivity was 95%. Of the 35 normal subjects, 27 had normal thallium images. The per patient specificity was 77%. The sensitivity and specificity for the individual vessels were 84% and 87% for the left anterior descending artery, 67% and 97% for the left circumflex artery, and 89% and 85% for the right coronary artery, respectively. Dipyridamole thallium-201 imaging is a relatively safe noninvasive method and is an effective alternative to exercise thallium-201 scintigraphy for the diagnosis of coronary artery disease.